Literature DB >> 7541008

Enhanced colonic nitric oxide generation and nitric oxide synthase activity in ulcerative colitis and Crohn's disease.

D Rachmilewitz1, J S Stamler, D Bachwich, F Karmeli, Z Ackerman, D K Podolsky.   

Abstract

Recent studies have suggested that nitric oxide (NO.), the product of nitric oxide synthase in inflammatory cells, may play a part in tissue injury and inflammation through its oxidative metabolism. In this study the colonic generation of oxides of nitrogen (NOx) and nitric oxide synthase activity was determined in ulcerative colitis and Crohn's disease. Colonic biopsy specimens were obtained from inflammatory bowel disease patients and from normal controls. Mucosal explants were cultured in vitro for 24 hours and NOx generation was determined. Nitric oxide synthase activity was monitored by the conversion of [3H]-L-arginine to citrulline. Median NOx generation by inflamed colonic mucosa of patients with active ulcerative colitis and Crohn's colitis was 4.2- and 8.1-fold respectively higher than that by normal human colonic mucosa. In ulcerative colitis and Crohn's colitis nitric oxide synthase activity was 10.0- and 3.8-fold respectively higher than in normal subjects. Colonic NOx generation is significantly decreased by methylprednisolone and ketotifen. The decrease in NOx generation by cultured colonic mucosa induced by methylprednisolone suggests that NO synthase activity is induced during the culture and the steroid effect may contribute to its therapeutic effect. Enhanced colonic NOx generation by stimulated nitric oxide synthase activity in ulcerative colitis and Crohn's disease may contribute to tissue injury.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7541008      PMCID: PMC1382676          DOI: 10.1136/gut.36.5.718

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  23 in total

1.  Oscillations in free cytosolic calcium during IgE-mediated stimulation distinguish human basophils from human mast cells.

Authors:  D MacGlashan; C B Guo
Journal:  J Immunol       Date:  1991-10-01       Impact factor: 5.422

Review 2.  Biosynthesis and metabolism of endothelium-derived nitric oxide.

Authors:  L J Ignarro
Journal:  Annu Rev Pharmacol Toxicol       Date:  1990       Impact factor: 13.820

3.  Ulcerative colitis: one disease or two? (Quantitative histological differences between distal and extensive disease).

Authors:  D Jenkins; A Goodall; B B Scott
Journal:  Gut       Date:  1990-04       Impact factor: 23.059

4.  Role of platelet-activating factor in ulcerative colitis. Enhanced production during active disease and inhibition by sulfasalazine and prednisolone.

Authors:  R Eliakim; F Karmeli; E Razin; D Rachmilewitz
Journal:  Gastroenterology       Date:  1988-11       Impact factor: 22.682

5.  Role of prostaglandins in ulcerative colitis. Enhanced production during active disease and inhibition by sulfasalazine.

Authors:  P Sharon; M Ligumsky; D Rachmilewitz; U Zor
Journal:  Gastroenterology       Date:  1978-10       Impact factor: 22.682

6.  Protective effect of S-nitroso-N-acetyl-penicillamine in endotoxin-induced acute intestinal damage in the rat.

Authors:  N K Boughton-Smith; I R Hutcheson; A M Deakin; B J Whittle; S Moncada
Journal:  Eur J Pharmacol       Date:  1990-12-04       Impact factor: 4.432

7.  Widespread tissue distribution, species distribution and changes in activity of Ca(2+)-dependent and Ca(2+)-independent nitric oxide synthases.

Authors:  M Salter; R G Knowles; S Moncada
Journal:  FEBS Lett       Date:  1991-10-07       Impact factor: 4.124

8.  Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide.

Authors:  J S Beckman; T W Beckman; J Chen; P A Marshall; B A Freeman
Journal:  Proc Natl Acad Sci U S A       Date:  1990-02       Impact factor: 11.205

9.  Role of interleukin 1 in inflammatory bowel disease--enhanced production during active disease.

Authors:  M Ligumsky; P L Simon; F Karmeli; D Rachmilewitz
Journal:  Gut       Date:  1990-06       Impact factor: 23.059

10.  L-arginine is required for expression of the activated macrophage effector mechanism causing selective metabolic inhibition in target cells.

Authors:  J B Hibbs; Z Vavrin; R R Taintor
Journal:  J Immunol       Date:  1987-01-15       Impact factor: 5.422

View more
  85 in total

1.  Potentiation of cytokine induced iNOS expression in the human intestinal epithelial cell line, DLD-1, by cyclic AMP.

Authors:  M Cavicchi; B J Whittle
Journal:  Gut       Date:  1999-09       Impact factor: 23.059

Review 2.  Peroxynitrite and inflammatory bowel disease.

Authors:  D M McCafferty
Journal:  Gut       Date:  2000-03       Impact factor: 23.059

Review 3.  Small therapeutic molecules for the treatment of inflammatory bowel disease.

Authors:  S J H van Deventer
Journal:  Gut       Date:  2002-05       Impact factor: 23.059

4.  Increases in free radicals and cytoskeletal protein oxidation and nitration in the colon of patients with inflammatory bowel disease.

Authors:  A Keshavarzian; A Banan; A Farhadi; S Komanduri; E Mutlu; Y Zhang; J Z Fields
Journal:  Gut       Date:  2003-05       Impact factor: 23.059

5.  Distinct immune response induced by peptidoglycan derived from Lactobacillus sp.

Authors:  Jin Sun; Yong-Hui Shi; Guo-Wei Le; Xi-Yi Ma
Journal:  World J Gastroenterol       Date:  2005-10-28       Impact factor: 5.742

6.  Stress increases susceptibility to oxidative/nitrosative mucosal damage in an experimental model of colitis in rats.

Authors:  Arturo L Colón; José L M Madrigal; Luis A Menchén; María A Moro; Ignacio Lizasoain; Pedro Lorenzo; Juan C Leza
Journal:  Dig Dis Sci       Date:  2004-10       Impact factor: 3.199

Review 7.  Nitric oxide as a modulator of intestinal water and electrolyte transport.

Authors:  A A Izzo; N Mascolo; F Capasso
Journal:  Dig Dis Sci       Date:  1998-08       Impact factor: 3.199

8.  Nrf2 is not required for epithelial prohibitin-dependent attenuation of experimental colitis.

Authors:  Arwa S Kathiria; Mackenzie A Butcher; Jason M Hansen; Arianne L Theiss
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2013-03-14       Impact factor: 4.052

9.  Tumor suppressor function of the plasma glutathione peroxidase gpx3 in colitis-associated carcinoma.

Authors:  Caitlyn W Barrett; Wei Ning; Xi Chen; Jesse Joshua Smith; Mary K Washington; Kristina E Hill; Lori A Coburn; Richard M Peek; Rupesh Chaturvedi; Keith T Wilson; Raymond F Burk; Christopher S Williams
Journal:  Cancer Res       Date:  2012-12-05       Impact factor: 12.701

10.  Hyperbaric oxygen: a novel modality to ameliorate experimental colitis.

Authors:  D Rachmilewitz; F Karmeli; E Okon; I Rubenstein; O S Better
Journal:  Gut       Date:  1998-10       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.